AP/Houston Chronicle Examines Gender Differences In Lung Cancer, Current Studies On Issue

Main Category: Lung Cancer
Article Date: 01 Jun 2006 - 0:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:not yet rated

Healthcare Prof:not yet rated


The AP/Houston Chronicle on Monday examined gender differences in the development of lung cancer and three studies that are examining whether estrogen can be linked to the differences. Lung cancer this year is expected to cause the deaths of an estimated 162,000 people in the U.S., 72,000 of whom likely will be women. In addition, rates of lung cancer deaths among women are "stubbornly holding steady" in recent years, while the rates of lung cancer deaths among men have decreased, the AP/Chronicle reports. However, women on average survive longer after developing lung cancer than men, and the newest drugs to treat the disease, Tarceva and Iressa, have been more effective in women. The National Cancer Institute is funding a 720-person study -- led by Kathy Albain, a lung cancer specialist at Loyola University Health System -- to identify genes, hormones or other factors explaining the gender differences. In addition, University of Pittsburgh pharmacologist Jill Siegfried is leading a 120-person study examining whether women taking Tarceva respond better if also given the antiestrogen drug Faslodex. According to the AP/Chronicle, Siegfried's research indicates estrogen might "fuel" lung tumors as it does in many types of breast tumors. Seattle-based Cell Therapeutics also is testing the efficacy of the experimental lung cancer drug Xyotax. Previous studies find that women living with lung cancer using Xyotax had a survival rate of 45% after one year, compared with 25% among women taking standard regimens and 25% among men given either regimen, according to the AP/Chronicle (Neergaard, AP/Houston Chronicle, 5/29).

"Reprinted with permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation . © 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.

View drug information on Faslodex; Iressa; Tarceva.


Article adapted by Medical News Today from original press release.
Visit our lung cancer section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Oliver Atkins. "AP/Houston Chronicle Examines Gender Differences In Lung Cancer, Current Studies On Issue." Medical News Today. MediLexicon, Intl., 1 Jun. 2006. Web.
15 Feb. 2012. <http://www.medicalnewstoday.com/releases/44370.php>

APA
Oliver Atkins. (2006, June 1). "AP/Houston Chronicle Examines Gender Differences In Lung Cancer, Current Studies On Issue." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/44370.php.

Please note: If no author information is provided, the source is cited instead.


Lung Cancer

What is Lung Cancer?

Cancer is a class of diseases characterized by out-of-control cell growth, and lung cancer occurs when this uncontrolled cell growth begins in one or both lungs. Rather than developing into healthy, normal lung tissue, these abnormal cells continue... Read more...

Most Popular Articles



Follow Our Lung Cancer News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Lung Cancer Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »